Our follow-on strategy with VT-122 is aimed at patients with recurrent prostate cancer that are receiving androgen inhibition therapy and with markers of disease progression including rising PSA and elevated Bone Turnover Markers. This type of prostate cancer represents approximately 20% of all prostate cancer cases receiving androgen inhibition therapy. In the US, we are initially focused on the treatment of pre-chemo patients receiving 2nd generation androgen inhibition therapy with rising PSA.
Despite advances in the treatment of these patients with rising PSA, most will progress within one year and proceed to chemotherapy and other palliative therapies with an expected survival of less than three years. We believe that our strategy to damp tumor-promoting inflammation and enhance immune system suppression of cancer with VT-122 may significantly improve outcomes for pre-chemo prostate cancer patients.